PerkinElmer and Cerep : Partners for Custom Drug Discovery Solutions

Apr 06, 2008 - PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, and Cerep SA (Eurolist: Cerep), a leading provider of drug candidate screening and profiling technologies, today announced the signing of a supply and co-marketing agreement to deliver custom drug discovery services. Under the terms of the agreement, PerkinElmer will exclusively market
Cerep's target screening and profiling services to its customers, and the companies will jointly promote PerkinElmer's assay technologies and Cerep services to the drug discovery market... [PDF] Cerep's Press Release - PDF du Communiqué de Presse CEREP -

Cerep, to provide profiling services to support a drug discovery program for Spinal Muscular Atrophy

Paris, France, January 31 , 2008 – Cerep [Eurolist: Cerep] is pleased to announce that it has been selected by Science Applications International Corporation (SAIC) on behalf of the Spinal Muscular Atrophy (SMA) Project through the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health to provide in vitro pharmacological profiling and ADME/Tox services for a multi-year program... english [PDF] Cerep's Press Release - français [PDF] Communiqué de Presse Cerep-